InvestSMART

Invex Therapeutics Ltd (ASX: IXC) - Announcements

- Current share price for IXC : $0.110

ASX company news and announcements for Invex Therapeutics Ltd (IXC) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Invex Therapeutics Ltd (IXC) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Invex Therapeutics Ltd (IXC), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Invex Therapeutics Ltd (IXC)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$8 Reinstatement to Quotation 30 Sep 2025 9:55AM $0.160 $0.110 fallen by 31.25%
$8 Response to ASX Price and Volume Query 30 Sep 2025 9:55AM $0.160 $0.110 fallen by 31.25%
$8 Corporate Update 30 Sep 2025 9:55AM $0.160 $0.110 fallen by 31.25%
$8 Director Nominations AGM 29 Sep 2025 12:09PM $0.160 $0.110 fallen by 31.25%
$8 Request for extension to voluntary suspension 29 Sep 2025 9:27AM $0.160 $0.110 fallen by 31.25%
$8 Suspension from Quotation 25 Sep 2025 9:40AM $0.160 $0.110 fallen by 31.25%
$8 Trading Halt 23 Sep 2025 11:35AM $0.160 $0.110 fallen by 31.25%
$8 Pause in Trading 23 Sep 2025 10:38AM $0.165 $0.110 fallen by 33.33%
$8 Notices received under sections 203D(2) and 249D of Corp Act 18 Sep 2025 10:42AM $0.130 $0.110 fallen by 15.38%
$8 Appendix 4G and Corporate Governance Statement 11 Aug 2025 9:39AM $0.090 $0.110 risen by 22.22%
$8 Appendix 4E and Annual Report to shareholders 11 Aug 2025 8:22AM $0.090 $0.110 risen by 22.22%
$8 Quarterly Activities/Appendix 4C Cash Flow Report 23 Jul 2025 8:11AM $0.097 $0.110 risen by 13.40%
$8 Quarterly Activities/Appendix 4C Cash Flow Report 8 Apr 2025 12:12PM $0.067 $0.110 risen by 64.18%
$8 Details of Company Address 20 Feb 2025 6:33PM $0.075 $0.110 risen by 46.67%
$8 Appendix 4D and Half Year Report 7 Feb 2025 9:30AM $0.073 $0.110 risen by 50.68%
$8 Quarterly Activities/Appendix 4C Cash Flow Report 22 Jan 2025 9:02AM $0.072 $0.110 risen by 52.78%
$8 Invex Receives $0.22m R&D Tax Rebate from UK Government 20 Jan 2025 9:25AM $0.072 $0.110 risen by 52.78%
$8 Improved Neuronal Cell Survival in 3D Model of Alzheimer's 16 Dec 2024 9:18AM $0.074 $0.110 risen by 48.65%
$8 Results of Meeting 26 Nov 2024 3:25PM $0.067 $0.110 risen by 64.18%
$8 Chair's Address to Shareholders 26 Nov 2024 1:23PM $0.070 $0.110 risen by 57.14%
$8 Addendum to Notice of Annual General Meeting 17 Oct 2024 12:27PM $0.086 $0.110 risen by 27.91%
$8 Letter to Shareholders AGM 14 Oct 2024 4:26PM $0.086 $0.110 risen by 27.91%
$8 Notice of Annual General Meeting 14 Oct 2024 4:23PM $0.086 $0.110 risen by 27.91%
$8 Quarterly Activities Report and Appendix 4C 8 Oct 2024 10:32AM $0.083 $0.110 risen by 32.53%
$8 Date of AGM and Closing Date for Director Nominations 23 Sep 2024 4:22PM $0.074 $0.110 risen by 48.65%

26 - 50 of 300 results

Page 2 of 12

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.